Merck & Co., Inc. (LON:0QAH)

Market Cap	158.29B
Revenue (ttm)	49.47B
Net Income (ttm)	13.49B
Shares Out	n/a
EPS (ttm)	5.32
PE Ratio	11.73
Forward PE	9.46
Dividend	2.44 (2.91%)
Ex-Dividend Date	Jun 16, 2025

Volume	57,714
Average Volume	16,653
Open	83.72
Previous Close	83.85
Day's Range	83.54 - 84.45
52-Week Range	71.70 - 129.38
Beta	0.40
RSI	59.15
Earnings Date	Jul 29, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAH

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD